About this Research Topic
This Research Topic will address novel strategies to improve clinical immunotherapy for Hodgkin and non-Hodgkin lymphomas. New approaches to enhance innate and adaptive immune responses to cancer will highlighted. Relevant preclinical and clinical studies will provide the basis for improved treatment of lymphoid neoplasms.
We are interested in Original Research, Clinical Trials, Systematic Reviews, Reviews/Mini-Reviews, and Perspectives articles focusing on but not limited to the following areas:
- Tumor microenvironment in Hodgkin and non-Hodgkin lymphomas
- Immune defects in Hodgkin and non-Hodgkin lymphomas
- Studies of innate and adaptive immune responses relevant to immunotherapy for lymphoma
- Use of cellular therapies in Hodgkin and non-Hodgkin lymphomas
- Novel approaches to autologous or allogeneic stem cell transplantation
- Novel combinations with immune checkpoint inhibitors
- Novel combinations with monoclonal antibodies and bispecific antibodies
- Use of antibody-drug conjugates in the treatment of Hodgkin and non-Hodgkin lymphomas
- Cytokine-based immunotherapy for lymphoma
- Vaccine-based immunotherapy for lymphoma
Topic Editor Prof. Eric Vivier is the co-founder and employee of Innate Pharma. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Keywords: Innate immunity, adaptive immunity, cellular therapy, bispecific antibodies, antibody-drug conjugates, immunotherapy, lymphoma
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.